Supplementary material to article by N. Loft et al. “Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study”

Fig. S1. Hazard ratios of treatment stop due to all causes for adalimumab, etanercept, infliximab, ustekinumab, secukinumab, and all treatments combined, for the different response groups compared with Psoriasis Area and Severity Index (PASI)=0.

![Graph showing drug survival with hazard ratios and p-values for different response groups.]

- Adalimumab
- Etanercept
- Infliximab
- Ustekinumab
- Secukinumab
- Overall